Enumeral Biomedical (ENUM) 0.1800 $ENUM Enumeral Reports

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Enumeral Biomedical (ENUM) 0.1800 $ENUM

Enumeral Reports Second Quarter Financial Results
BusinessWire - Fri Aug 12, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company", a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced its financial results for the quarter ended June 30, 2016.

Enumeral Announces Sale of 12% Senior Secured Promissory Notes
BusinessWire - Mon Aug 01, 6:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that on July 29, 2016 the Company sold 12% Senior Secured Promissory Notes (the "Notes" in a private placement offering to certain accredited investors in the aggregate principal amount of $3,038,256, before deducting placement agent fees and expenses equal to approximately $385,337 (the "Offering". The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.

Enumeral Receives Maintenance Fee to Continue License Agreement with Pieris and Enters into Definitive License Agreement
BusinessWire - Mon Jun 06, 5:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that, as contemplated in the April 18, 2016 License and Transfer Agreement (the "License Agreement", it has received a $750,000 license maintenance fee from and entered into a Definitive License and Transfer Agreement (the "Definitive Agreement" with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, "Pieris" to continue Pieris' license to Enumeral's 388D4 anti-PD-1 antibody.

Enumeral Reports First Quarter Financial Results
BusinessWire - Fri May 13, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company", a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced its financial results for the three months ended March 31, 2016.

Enumeral Announces Additional Data on Its Novel Class of PD-1 Antagonist to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting
BusinessWire - Mon Apr 18, 7:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it will present research findings on the Company's novel class of anti-PD-1 antibodies in a poster at the AACR Annual Meeting 2016 in New Orleans.

Enumeral and Pieris Pharmaceuticals Enter into License and Transfer Agreement
BusinessWire - Mon Apr 18, 5:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it has entered into a License and Transfer Agreement (the "License Agreement" with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, "Pieris".
PIRS: 1.63 (-0.03)

Enumeral to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
BusinessWire - Thu Mar 31, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present at the 3rd Annual Jefferies Immuno-Oncology Summit at 3:25 pm Eastern Time in the North Atlantic Room of the Boston Harbor Hotel on Thursday, April 7, 2016. The Summit is being held at the Boston Harbor Hotel, Boston Massachusetts, on April 7-8, 2016.

Enumeral Reports Fourth Quarter and Year-End 2015 Financial Results
BusinessWire - Wed Mar 30, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2015.

Enumeral to Present at the Noble Financial Capital Markets' 12th Annual Investor and Equity Conference
BusinessWire - Tue Jan 19, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present at the Noble Financial Capital Markets' 12th Annual Investor and Equity Conference on Wednesday, January 20, 2016 at 10:00 am Eastern Time. In addition, Dr. Tinkelenberg will be participating in a panel discussion entitled "The Brave New World of Cancer Immunotherapy" at 5:15 pm Eastern Time on Tuesday, January 19, 2016. The conference is being held at the Club Med in Sandpiper Bay, FL.

Enumeral and MD Anderson Enter Into Collaborative Research and Development Agreement
BusinessWire - Mon Jan 11, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) today announced that it has entered into a Collaborative Research and Development Agreement with The University of Texas MD Anderson Cancer Center.

Enumeral Presents Research Results for Novel Class of Anti-PD-1 Antibodies at AACR's 2016 Tumor Microenvironment Special Conference
BusinessWire - Fri Jan 08, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced the presentation of research findings for the Company's novel class of anti-PD-1 antibodies at the Function of the Tumor Microenvironment in Cancer Progression Conference, sponsored by the American Association for Cancer Research (AACR) and taking place in San Diego, CA, from January 7-10, 2016. Enumeral is advancing a novel class of potentially allosteric anti-PD-1 antibodies with distinctive properties compared to currently marketed anti-PD-1 antagonists, including a mechanism of action that does not appear to require the disruption of PD-1 interaction with PD-L1.

Enumeral to Participate in the 2016 East/West CEO Conference
BusinessWire - Wed Jan 06, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will participate in the 2016 East/West CEO Conference on the panel entitled "Academia and Industry: Challenges and Synergies," on Sunday, January 10, 2016 at 1:30 p.m. Pacific Time. The conference will be held at the Four Seasons Hotel in San Francisco, CA.

Enumeral to Present at Biotech Showcase 2016
BusinessWire - Tue Jan 05, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present a corporate overview at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 9:30 a.m. Pacific Time at the Parc 55 Hotel in San Francisco, CA.

Enumeral to Present at the Oppenheimer 26th Annual Healthcare Conference
BusinessWire - Tue Dec 01, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8th, 2015 at 3:20 p.m. ET at The Westin New York Grand Central Hotel in New York City.

Enumeral Reports Third Quarter 2015 Financial Results and Provides Corporate Update
BusinessWire - Tue Nov 10, 3:30PM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended September 30, 2015.

Enumeral Reports That Its Novel Class of Anti-PD-1 Antibodies Elicits Higher T Cell Activation in Ex Vivo Human Assays than Currently Marketed Anti-PD-1 Antibodies
BusinessWire - Tue Nov 03, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral researchers have demonstrated greater functional activity of its novel class of anti-PD-1 antibodies (as measured by restoration of T cell function in cell-based assays) when compared to conventional anti-PD-1 antibodies that disrupt PD-1 interaction with PD-L1. Enumeral's potentially allosteric antibodies block PD-L1-mediated immunosuppression, but do not disrupt PD-1 interaction with PD-L1.

Enumeral to Present at the Emerging Concepts in Host Response to Cancer Symposium at The University of Texas MD Anderson Cancer Center
BusinessWire - Mon Oct 05, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that the company will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at The University of Texas MD Anderson Cancer Center's Emerging Concepts in Host Response to Cancer Symposium Symposia. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster will be presented at MD Anderson Cancer Center's R. Lee Clark Clinic, 1515 Holcombe Boulevard, Floor 11, in Houston, Texas on October 8, 2015.

Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action
BusinessWire - Thu Sep 24, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 and LAG-3 antibody programs.

Enumeral to Present at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference and BioPharm America 2015
BusinessWire - Fri Sep 11, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Enumeral will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at the International Cancer Immunotherapy Conference. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster number is B083, and will be presented in the Empire Ballroom at the Sheraton New York Times Square Hotel in New York City from 4:45 pm to 6:45 pm on September 18, 2015.

Enumeral Reports Second Quarter 2015 Financial Results
BusinessWire - Wed Aug 12, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended June 30, 2015.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 53

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 39

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 569

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 44

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 84

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 113

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Mastering Prescription Labels: Critical Insights for Safety

Updated Category News Views 0

Revolutionizing How We Approach Prescription Labels Prescription labels aren't just scraps of paper or stickers slapped on bottles; they're lifelines. The insight from pharmacy expert Sheldon Birch could turn a regular label into a powerful tool for health management. According to Birch, the label is often disregarded yet speaks volumes about the medication you've got in...

Continue Reading

Top 5 Most Recently Viewed Articles

Ray Dalio Warns of Economic Heart Attack and Gold Investment

Updated Category News Views 330

Debt-Fueled Risks in the U.S. Economy Ray Dalio, founder of Bridgewater Associates, has recently shared his concerns regarding the growing debt burden facing the U.S. economy. According to Dalio, this financial strain resembles arterial blockage, leading to the possibility of a severe economic "heart attack." His warning speaks volumes as the national debt continues to...

Continue Reading
Citi Projects Stronger Global Economic Growth in 2024

Updated Category News Views 249

Global Economic Outlook for 2024 In a recent report, Citi's group of economists has expressed optimism about the global economic scene for 2024. They predict that the economy will exceed earlier expectations, thanks in part to lower interest rates and positive trends emerging from several markets. These elements create a more encouraging environment for growth compared to...

Continue Reading
Quarterhill Welcomes David Charron as CFO to Drive Growth

Updated Category News Views 226

David Charron Takes the Helm as Quarterhill's CFO Quarterhill Inc. (TSX: QTRH) is excited to announce that David Charron has been appointed as the new Chief Financial Officer (CFO). This strategic move comes as the company gears up for its next phase of growth. David brings over 15 years of experience in leadership roles within public technology companies, making him a...

Continue Reading
Autolus Therapeutics: Key Insights Ahead of Earnings Release

Updated Category News Views 209

Overview of Autolus Therapeutics Earnings Report Autolus Therapeutics (NASDAQ: AUTL) is preparing to share its quarterly earnings results soon. Investors are keenly anticipating this announcement, which will give them a clearer picture of the company’s performance and future direction. Forecasts and Market Expectations Analysts are projecting a loss per share (EPS) of...

Continue Reading
Blue Diamond Growers Earns Star Site Award for Safety Excellence

Updated Category News Views 299

Blue Diamond Growers Achieves Recognition for Safety Standards Blue Diamond Growers, the leading cooperative in almond marketing and processing, has reached a significant milestone by receiving the "Star Site" designation from Cal/OSHA. This recognition is awarded to employers who have excelled in managing safety and health programs effectively. Exceptional Safety at the...

Continue Reading